

CITATION REPORT

List of articles citing

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

**DOI: 10.1016/0304-3940(94)90746-3
Neuroscience Letters, 1994, 165, 208-10.**

Source: <https://exaly.com/paper-pdf/25269876/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
822	Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. <i>Neuroscience Letters</i> , 1994 , 180, 147-50	3.3	659
821	Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. 1995 , 92, 11294-8		344
820	Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. 1995 , 41, 717-26		123
819	Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. 1995 , 9, 87-92		75
818	Hypertriglyceridemia associated with tumor necrosis factor-alpha in hamster cheek-pouch carcinogenesis. 1995 , 74, 1558-63		8
817	The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. 1995 , 21, 195-218		1110
816	Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. <i>Neuroscience Letters</i> , 1995 , 193, 129-32	3.3	130
815	Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. <i>Neuroscience Letters</i> , 1995 , 202, 17-20	3.3	618
814	Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection. 1996 , 786, 206-16		17
813	Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. <i>Neuroscience Letters</i> , 1996 , 208, 85-8	3.3	75
812	Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. <i>Neuroscience Letters</i> , 1996 , 211, 13-6	3.3	417
811	bcl-2 Protein is increased in the brain from parkinsonian patients. <i>Neuroscience Letters</i> , 1996 , 215, 137-139		99
810	Production of tumor necrosis factor in spinal cord following traumatic injury in rats. 1996 , 69, 151-6		129
809	The soluble form of Fas molecule is elevated in parkinsonian brain tissues. <i>Neuroscience Letters</i> , 1996 , 220, 195-8	3.3	83
808	Cytokines et cerveau. 1996 , 36, 319-326		
807	Section Review Central & Peripheral Nervous Systems: Mechanisms of apoptosis as drug targets in the central nervous system. 1996 , 6, 345-366		3
806	Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-alpha and interleukin-6 in serum. 1996 , 41, 513-6		2

805	Glial expression of cytokines in the brains of cerebrovascular disease patients. 1996 , 92, 281-7		75
804	The role of inflammation and cytokines in brain injury. 1996 , 20, 445-52		333
803	Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. 1996 , 103, 1077-81		64
802	Interleukin (IL)-1 beta, IL-6, tumor necrosis factor-alpha, epidermal growth factor, and beta 2-microglobulin levels are elevated in gingival crevicular fluid during human orthodontic tooth movement. 1996 , 75, 562-7		241
801	Interferon-gamma potentiates interleukin (IL)-6 and tumor necrosis factor-alpha but not IL-1beta induced by endotoxin in the brain. 1997 , 138, 5220-6		26
800	Inhibition of p75 Tumor Necrosis Factor Receptor by Antisense Oligonucleotides Increases Hypoxic Injury and β -Amyloid Toxicity in Human Neuronal Cell Line. 1997 , 272, 3550-3553		73
799	The neuroimmune hypothesis in Parkinson's disease. 1997 , 8, 29-34		14
798	T-lymphocyte tumor necrosis factor-alpha receptor binding in patients with Parkinson's disease. 1997 , 149, 41-5		14
797	Inflammatory Cytokines in the CNS. 1997 , 7, 214-228		25
796	Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. 1997 , 74, 173-84		35
795	Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. <i>Neuroscience Letters</i> , 1997 , 234, 123-6	3-3	37
794	TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. <i>Neuroscience Letters</i> , 1997 , 238, 65-8	3-3	43
793	Tumor necrosis factor-alpha: a neuromodulator in the CNS. 1997 , 21, 603-13		150
792	Neurodegeneration induced by MoMuLV-ts1 and increased expression of Fas and TNF-alpha in the central nervous system. 1998 , 779, 1-8		49
791	Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. 1998 , 795, 349-57		36
790	Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. 1998 , 801, 1-8		75
789	Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum. <i>Neuroscience Letters</i> , 1998 , 250, 25-8	3-3	61
788	Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-alpha. 1998 , 63, 571-6		41

787	Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. 1998 , 44, S115-20		259
786	Cytokine-neurotransmitter interactions in the brain. 1998 , 7, 33-44		38
785	Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. 1998 , 55, 1075-80		97
784	Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. 1999 , 56, 194-200		43
783	Anti-proliferative capsular-like polysaccharide antigen from <i>Actinobacillus actinomycetemcomitans</i> induces apoptotic cell death in mouse osteoblastic MC3T3-E1 cells. 1999 , 78, 1230-7		31
782	The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. 1999 , 890, 7-25		76
781	Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. 1999 , 819, 170-3		43
780	Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. 1999 , 46, 598-605		791
779	Nerve growth factor inhibits apoptosis induced by tumor necrosis factor in PC12 cells. 1999 , 55, 269-77		32
778	NGF-resistant PC12 cell death induced by arachidonic acid is accompanied by a decrease of active PKC zeta and nuclear factor kappa B. 1999 , 57, 219-26		44
777	Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. <i>Neuroscience Letters</i> , 1999 , 268, 101-4	3-3	72
776	Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. <i>Neuroscience Letters</i> , 1999 , 270, 45-8	3-3	302
775	Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. 1999 , 69, 135-43		116
774	Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. 1999 , 160, 124-32		113
773	Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. 2000 , 101, 159-64		56
772	Glial cells and Parkinson's disease. 2000 , 247 Suppl 2, I158-62		43
771	Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. 2000 , 107, 335-41		219
770	Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. 2000 , 107, 553-62		82

769	Changes in cytokines and neurotrophins in Parkinson's disease. 2000 , 277-90		194
768	Cytokines in Parkinson's disease. 2000 , 143-151		39
767	Advances in Research on Neurodegeneration. 2000 ,		0
766	Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. 2000 , 16, 724-39		389
765	The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. 2000 , 7, 429-47		318
764	Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. <i>Neuroscience Letters</i> , 2000 , 289, 165-8	3-3	50
763	Inflammation and Alzheimer's disease. 2000 , 21, 383-421		3490
762	Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?. 2000 , 20, 253-7		185
761	Advances in Research on Neurodegeneration. 2000 ,		
760	Rat extracorporeal circulation model for evaluation of systemic immunotoxicity. 2000 , 115, 63-70		5
759	Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. 2001 , 169, 219-30		177
758	Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-alpha. 2001 , 106, 137-48		45
757	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. 2001 , 65, 135-72		933
756	Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. <i>Neuroscience Letters</i> , 2001 , 300, 179-81	3-3	42
755	High-performance immunoaffinity chromatography, an immunoaffinity membrane for selective removal of plasma components, and safety evaluation of the latter system. 2001 , 49, 241-51		10
754	Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. 2001 , 96, 103-13		51
753	Alpha-synuclein expression is up-regulated in Ntera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors. 2001 , 8, 7-17		16
752	Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. 2001 , 15, 351-5		24

751	Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. 2001 , 21, 8447-55	225
750	The role of glial cells in Parkinson's disease. 2001 , 14, 483-9	254
749	Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. 2001 , 21, 2247-55	222
748	Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. 2001 , 32, 1750-8	160
747	Neurochemical findings in the MPTP model of Parkinson's disease. 2001 , 108, 1263-82	221
746	Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. 2001 , 78, 1073-82	420
745	Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress. 2001 , 27, 95-104	28
744	TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. 2001 , 64, 121-31	79
743	Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. 2001 , 39, 167-74	247
742	Regulation of blood-brain barrier permeability. 2001 , 8, 89-104	104
741	Neuronal Death by Accident or by Design. 2001 ,	
740	Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. 2001 , 155, 217-26	99
739	Oxidative stress indices in Parkinson's disease : biochemical determination. 2001 , 62, 137-53	5
738	Inflammation and Parkinson's disease. 2002 , 1, 221-42	34
737	Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. 2002 , 16, 1474-6	301
736	Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. 2002 , 177, 183-92	70
735	An inflammatory review of Parkinson's disease. 2002 , 68, 325-40	267
734	Involvement of inflammatory cytokines in central nervous system injury. 2002 , 67, 161-72	220

733	Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. <i>Neuroscience Letters</i> , 2002 , 326, 70-2	3-3	87
732	Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. 2002 , 133, 27-35		154
731	Murine tumor necrosis factor-alpha sensitizes plasma corticosterone activity and the manifestation of shock: modulation by histamine. 2002 , 131, 60-9		19
730	Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. 2002 , 63, 21-9		260
729	In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. 2002 , 17, 116-24		184
728	Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. 2002 , 109, 731-45		62
727	Free radicals in Parkinson's disease. 2002 , 249 Suppl 2, II1-5		80
726	Relative contribution of different receptor subtypes in the response of neuroblastoma cells to tumor necrosis factor-alpha. 2000 , 75, 1172-9		13
725	The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. 2002 , 81, 150-7		180
724	Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. 2002 , 83, 167-75		71
723	Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. 1998 , 71, 88-94		161
722	Tumor necrosis factor-alpha increases lactoferrin transcytosis through the blood-brain barrier. 1999 , 73, 2491-500		32
721	Glial cell response: A pathogenic factor in Parkinson's disease. 2002 , 8, 551-8		31
720	Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. 2003 , 21, 191-8		65
719	Parkinson's disease and inflammatory changes. 2003 , 5, 411-8		63
718	Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations. 2003 , 5, 1-26		25
717	Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. 2003 , 73, 334-40		33
716	Pathogenic role of glial cells in Parkinson's disease. 2003 , 18, 121-9		224

715	Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. 2003 , 23, 9-15	49
714	Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. 2003 , 111, 1065-73	202
713	Neuroprotection by bioactive components in medicinal and food plant extracts. 2003 , 544, 203-15	80
712	Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb <i>Tripterygium wilfordii</i> Hook F, on dopaminergic neurons. 2003 , 179, 28-37	47
711	Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. 2003 , 12, 35-45	155
710	Neuroprotective strategies in Parkinson's disease : an update on progress. 2003 , 17, 729-62	166
709	Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. 2003 , 17, 500-2	232
708	Caspase-1 and caspase-8 cleave and inactivate cellular parkin. 2003 , 278, 23376-80	60
707	Pathogenic role of glial cells in Parkinson's disease. 2003 , 31, 967-982	6
706	Scintigraphic visualization of inflammation in neurodegenerative disorders. 2003 , 24, 209-21	7
705	Blood vessels and parkinsonism. 2004 , 9, 277-82	32
704	Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. 2004 , 24, 2226-35	49
703	Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. 2004 , 89, 822-33	160
702	Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. 2004 , 148, 24-31	60
701	Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice. 2004 , 152, 83-97	48
700	New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. 2004 , 1035, 290-315	76
699	Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. 2004 , 318, 149-61	296
698	Diagnostic staging of Parkinson's disease: conceptual aspects. 2004 , 111, 201-16	116

697	Antiapoptotic effects of budipine. 2004 , 111, 1365-73	
696	Tumor necrosis factor reduces cAMP production in rat microglia. 2004 , 48, 241-9	13
695	TNF alpha increases activity of gamma-glutamyl transpeptidase in cultured rat astroglial cells. 2004 , 75, 536-43	13
694	Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. 2004 , 76, 466-74	45
693	Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. 2004 , 15, 506-16	359
692	Inflammation and neurodegeneration in Parkinson's disease. 2004 , 10 Suppl 1, S3-7	416
691	The homozygote AA genotype of the alpha1-antichymotrypsin gene may confer protection against early-onset Parkinson's disease in women. 2004 , 10, 469-73	4
690	Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. 2004 , 29, 966-71	158
689	Bi-functional effects of ATP/P2 receptor activation on tumor necrosis factor-alpha release in lipopolysaccharide-stimulated astrocytes. 2005 , 92, 525-35	67
688	The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. 2005 , 22, 317-30	98
687	The MAP kinase pathway mediates transcytosis induced by TNF-alpha in an in vitro blood-brain barrier model. 2005 , 22, 835-44	31
686	Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. 2005 , 21, 1911-20	21
685	Peripheral lipopolysaccharide induces apoptosis in the murine olfactory bulb. 2005 , 1039, 116-29	13
684	In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization. 2005 , 1045, 31-7	7
683	Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. 2005 , 112, 111-9	77
682	Multiple system atrophy. 2005 , 623-662	2
681	Oxidative stress, antioxidants and neurodegenerative diseases. 2005 , 11, 2033-52	108
680	The role of early life environmental risk factors in Parkinson disease: what is the evidence?. 2005 , 113, 1234-8	86

679	Multiple System Atrophy. 2005 , 335-360		
678	Inflammatory process in Parkinson's disease: role for cytokines. 2005 , 11, 999-1016		324
677	Atypical Parkinsonian Disorders. 2005 ,		10
676	Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. 2005 , 11, 1017-30		106
675	Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice. 2005 , 138, 156-63		7
674	Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. 2005 , 19, 96-107		286
673	Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. <i>Neuroscience Letters</i> , 2005 , 375, 107-11	3-3	36
672	Differential inflammatory activation of IL-6 (-/-) astrocytes. 2005 , 30, 47-55		17
671	Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. 2005 , 193, 279-90		370
670	Blueberry- and spirulina-enriched diets enhance striatal dopamine recovery and induce a rapid, transient microglia activation after injury of the rat nigrostriatal dopamine system. 2005 , 196, 298-307		71
669	Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. 2005 , 135, 829-38		44
668	CSF proteome: a protein repository for potential biomarker identification. 2005 , 2, 57-70		99
667	Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. 2005 , 25, 3701-11		211
666	Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. 2006 , 20, 670-82		192
665	Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. 2006 , 8, E606-21		84
664	Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. 2006 , 27, 530-45		122
663	Mitochondria, oxidative damage, and inflammation in Parkinson's disease. 2003 , 991, 120-31		383
662	Cellular models to study dopaminergic injury responses. 2003 , 991, 140-51		25

661	Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. 2004 , 14, 275-80	43
660	Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. 2000 , 899, 262-73	62
659	Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. 2006 , 148, 314-25	97
658	Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. 2006 , 53-65	82
657	Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. 2006 , 26, 781-802	89
656	Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease. 2006 , 31, 85-94	63
655	Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. 2006 , 112, 517-30	92
654	Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. 2006 , 6, 261-281	251
653	Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. 2006 , 1118, 239-50	43
652	An inflammatory pathomechanism for Parkinson's disease?. 2006 , 13, 591-602	54
651	Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. 2006 , 38, 333-47	433
650	Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. 2007 , 179, 6204-14	50
649	Microglial activation and its implications in the brain diseases. 2007 , 14, 1189-97	689
648	TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. 2007 , 4, 378-85	152
647	Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. 2007 , 64, 836-40	121
646	Inflammation in the Pathogenesis of Chronic Diseases. 2007 ,	4
645	Green and Black Tea in Brain Protection. 2007 , 581-605	2
644	Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. 2007 , 28, 894-906	97

643	Non-steroidal anti-inflammatory drugs in Parkinson's disease. 2007 , 205, 295-312	170
642	Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. 2007 , 208, 1-25	397
641	p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. <i>Neuroscience Letters</i> , 2007 , 414, 94-7	3:3 186
640	Developmental switch in the effects of TNFalpha on ventral midbrain dopaminergic neurons. 2007 , 57, 296-305	28
639	Neuroinflammation and Parkinson's disease. 2007 , 83, 535-51	40
638	The role of anti-inflammatory agents in Parkinson's disease. 2007 , 21, 789-97	70
637	Programmed cell death in Parkinson's disease. 2007 , 83, 591-605	8
636	Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target. 2007 , 2, 77-90	5
635	Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. 2007 , 144B, 300-4	40
634	Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 2007 , 85, 1752-61	37
633	Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. 2007 , 8, 57-69	2906
632	Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. 2007 , 26, 1500-8	29
631	Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. 2007 , 101, 397-410	100
630	Cocaine exposure in vitro induces apoptosis in fetal locus coeruleus neurons through TNF-alpha-mediated induction of Bax and phosphorylated c-Jun NH(2)-terminal kinase. 2007 , 103, 542-56	26
629	TNFalpha and TNF receptor 1 expression in the mixed neuronal-glia cultures of hippocampal dentate gyrus exposed to glutamate or trimethyltin. 2007 , 1131, 17-28	57
628	Early inhibition of TNFalpha increases 6-hydroxydopamine-induced striatal degeneration. 2007 , 1147, 240-7	19
627	Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. 2007 , 54, 233-50	101
626	Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. 2007 , 192, 89-98	56

625	The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. 2007 , 8, 83-94		82
624	Src suppressed C kinase substrate regulates the lipopolysaccharide-induced TNF-alpha biosynthesis in rat astrocytes. 2007 , 32, 16-24		19
623	Divergent roles for tumor necrosis factor-alpha in the brain. 2007 , 2, 140-53		178
622	Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. 2008 , 56, 1199-214		55
621	Peripheral lipopolysaccharide administration affects the olfactory dopamine system in mice. 2008 , 1148, 127-35		8
620	Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. 2008 , 28, 707-16		31
619	Dual effects of TNFalpha on nerve fiber formation from ventral mesencephalic organotypic tissue cultures. 2008 , 1215, 30-9		10
618	Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. 2008 , 1216, 78-86		9
617	The influence of dexmedetomidine on ischemic rat hippocampus. 2008 , 1218, 250-6		63
616	Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. 2008 , 12, 2263-80		191
615	JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. 2008 , 204, 118-25		59
614	Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. 2008 , 32, 521-7		76
613	Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. 2008 , 5, 4		95
612	TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. 2008 , 5, 45		574
611	Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. <i>Neuroscience Letters</i> , 2008 , 441, 158-62	3-3	189
610	Protective role of interlekin-1 alpha gene polymorphism in Chinese Han population with sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2008 , 445, 23-5	3-3	16
609	A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetid-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. 2008 , 55, 654-60		16
608	Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. 2008 , 14, 46-51		37

607	Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. 2008 , 85, 1-74	222
606	Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. 2008 , 16, 1572-9	95
605	Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. 2008 , 28, 12052-61	49
604	Inflammatory cytokines in acute ischemic stroke. 2008 , 14, 3574-89	235
603	Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells. 2008 , 102, 254-61	42
602	Etiopathogenesis of Parkinson disease: a new beginning?. 2009 , 15, 28-35	60
601	[The relevance of the TNF-alpha system in psychiatric disorders]. 2009 , 77, 334-45	32
600	Inflammatory cytokines IL-1 β and TNF- β regulate p75 ^{NTR} expression in CNS neurons and astrocytes by distinct cell-type-specific signalling mechanisms. 2009 , 1,	45
599	Autoimmune disease and risk for Parkinson disease: a population-based case-control study. 2009 , 73, 1462-8	83
598	Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. 2009 , 216, 122-5	88
597	Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. 2009 , 215, 65-72	29
596	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. 2009 , 8, 382-97	1326
595	Beneficial effects of antioxidant-enriched diet for tyrosine hydroxylase-positive neurons in ventral mesencephalic tissue in oculo grafts. 2009 , 515, 72-82	4
594	Neurochemical biomarkers in the differential diagnosis of movement disorders. 2009 , 24, 1411-26	31
593	Astrocyte-neuron interactions in neurological disorders. 2009 , 35, 317-36	107
592	Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. 2009 , 4, 283-96	176
591	CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. 2009 , 16, 318-28	68
590	Circulating interleukin-10 and interleukin-12 in Parkinson's disease. 2009 , 119, 332-7	81

589	Targets for neuroprotection in Parkinson's disease. 2009 , 1792, 676-87	125
588	Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration. 2009 , 30, 1361-78	60
587	The influence of microglia on the pathogenesis of Parkinson's disease. 2009 , 89, 277-87	213
586	Cytokine Polymorphisms and Immunosenescence. 2009 , 631-658	
585	Inflammatory response in Parkinsonism. 2009 , 245-52	6
584	Increase of secondary processes of microglial and astroglial cells after MPTP-induced degeneration in substantia nigra pars compacta of non human primates. 2009 , 253-8	7
583	Glutathione--a review on its role and significance in Parkinson's disease. 2009 , 23, 3263-72	232
582	MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. 2009 , 123, 1261-70	42
581	Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. 2009 , 9, 1229-41	59
580	Glycogen synthase kinase-3 β inactivation inhibits tumor necrosis factor- β production in microglia by modulating nuclear factor B and MLK3/JNK signaling cascades. 2010 , 7, 99	85
579	The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease. 2004 , 56, 649-54	23
578	Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. 2010 , 24, 2533-45	168
577	Interleukin-1 β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. 2010 , 226, 20-6	38
576	α -Melanocyte-stimulating hormone modulates lipopolysaccharide plus interferon- β -induced tumor necrosis factor- β expression but not tumor necrosis factor- β receptor expression in cultured hypothalamic neurons. 2010 , 227, 52-9	13
575	Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. 2010 , 37, 510-8	726
574	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. 2010 , 39, 229-41	56
573	The roles of TNF in brain dysfunction and disease. 2010 , 128, 519-48	153
572	Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. 2010 , 22, 977-83	192

571	Transcriptional regulation of UCP4 by NF-kappaB and its role in mediating protection against MPP+ toxicity. 2010 , 49, 192-204		13
570	Microglial activation and chronic neurodegeneration. 2010 , 7, 354-65		611
569	Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain. 2010 , 7, 12		117
568	Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. 2010 , 24, 4989-5002		1
567	Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. 2010 , 3, 1812-1841		53
566	Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. 2010 , 4, 140		49
565	Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. 2010 , 5, e8784		173
564	Raf inhibitors as therapeutic agents against neurodegenerative diseases. 2010 , 9, 120-7		6
563	The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. 2010 , 44, 1304-16		32
562	Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. 2010 , 24, 4989-5002		66
561	Methanol induces a discrete transcriptional dysregulation that leads to cytokine overproduction in activated lymphocytes. 2010 , 117, 303-13		5
560	Vinpocetine as a potent antiinflammatory agent. 2010 , 107, 9921-2		51
559	Peripherally injected lipopolysaccharide induces apoptosis in the subventricular zone of young adult mice. <i>Neuroscience Letters</i> , 2010 , 481, 126-30	3-3	6
558	The protective effect of avocado soybean unsaponifiables on brain ischemia/reperfusion injury in rat prefrontal cortex. 2011 , 25, 701-6		8
557	Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. 2011 , 19, 46-52		86
556	MPTP and Oxidative Stress: It's Complicated!. 2011 , 187-209		1
555	Advances in TNF Family Research. 2011 ,		3
554	Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. 2011 , 25, 135-46		142

553	Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. 2011 , 219, 280-90	53
552	Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. 2011 , 69, 337-42	136
551	Cytokine expression and microglial activation in progressive supranuclear palsy. 2011 , 17, 683-8	51
550	Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. 2011 , 35, 380-9	52
549	Rosiglitazone decreases peroxisome proliferator receptor- β levels in microglia and inhibits TNF- β production: new evidences on neuroprotection in a progressive Parkinson's disease model. 2011 , 194, 250-61	109
548	Pharmacological therapy in Parkinson's disease: focus on neuroprotection. 2011 , 17, 345-67	23
547	The duality of TNF signaling outcomes in the brain: potential mechanisms?. 2011 , 229, 198-200	13
546	The Role of Neuroinflammation in Parkinson's Disease. 2011 , 403-421	4
545	Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. 2011 , 2011, 393769	26
544	Bridging molecular genetics and biomarkers in lewy body and related disorders. 2011 , 2011, 842475	5
543	The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation. 2011 , 2011, 931572	3
542	The endotoxin-induced neuroinflammation model of Parkinson's disease. 2011 , 2011, 487450	58
541	Transcriptional Factor NF- κ B as a Target for Therapy in Parkinson's Disease. 2011 , 2011, 216298	54
540	The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. 2011 , 2011, 716859	50
539	Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?. 2011 , 2011, 689181	33
538	Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. 2011 , 164, 1357-91	443
537	Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. 2011 , 670, 441-7	56
536	Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. 2011 , 26, 2364-70	16

535	Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system. 2011 , 13, 251-65	26
534	The role of tumor necrosis factor- α and TNF- β receptors in cerebral arteries following cerebral ischemia in rat. 2011 , 8, 107	65
533	The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. 2011 , 8, 137	27
532	CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. 2011 , 8, 154	102
531	The acute inflammatory response to intranigral β -synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. 2011 , 8, 166	118
530	Glia: initiators and progressors of pathology in Parkinson's disease. 2011 , 26, 6-17	308
529	Studies on Experimental Models. 2011 ,	
528	IFN- β signaling, with the synergistic contribution of TNF- β mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. 2011 , 2, e142	140
527	MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. 2011 , 18, 79-88	78
526	Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. 2011 , 10, 849-62	37
525	Neurobiology of vascular dementia. 2011 , 2011, 401604	15
524	Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. 2012 , 26, 334-45	67
523	Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants. 2012 ,	6
522	Innate inflammation in Parkinson's disease. 2012 , 2, a009373	78
521	Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease. 2012 , 18, 200-8	51
520	Imaging of microglia in patients with neurodegenerative disorders. 2012 , 3, 96	85
519	Cytokine gene polymorphisms and Parkinson's disease: a meta-analysis. 2012 , 39, 58-64	23
518	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. 2012 , 56, 508-13	34

517	Inflammation in Parkinson's disease. 2012 , 88, 69-132	130
516	Interferon- γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. 2012 , 33, 1411-26	67
515	Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. 2012 , 62, 2154-68	203
514	Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. 2012 , 98, 222-38	76
513	Rosiglitazone, a PPAR- α agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. 2012 , 213, 332-44	46
512	The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. 2012 , 9, 66	40
511	Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. 2012 , 166, 2317-30	48
510	Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. 2012 , 87, 10-20	573
509	Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. 2012 , 9, 234	12
508	Proteolytic activation of proapoptotic kinase protein kinase C β by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. 2012 , 9, 82	51
507	Parkinson's disease and immune system: is the culprit LRRK in the periphery?. 2012 , 9, 94	29
506	Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. 2012 , 144, 506-13	17
505	The role of microglia-lymphocyte interaction in PD neuropathology. 2012 , 2, 123-130	1
504	Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells. 2012 , 26, 1322-30	48
503	Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. 2012 , 60, 762-6	88
502	Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials. 2012 , 28, 407-17	8
501	Alpha-synuclein: from secretion to dysfunction and death. 2012 , 3, e350	199
500	Microglia activation-induced mesencephalic dopaminergic neurodegeneration in an in vitro model for Parkinson's disease. 2012 , 7, 404-411	

499	Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. 2012 , 7, 45	38
498	Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study. 2012 , 2012, 214714	37
497	Antioxidant-Enriched Diet Affects Early Microglia Accumulation and Promotes Regeneration of the Striatal Dopamine System after a 6-Hydroxidopamine-Induced Lesion in a Rat. 2012 , 6, JEN.S10424	2
496	Adjunctive therapy in Parkinson's disease: the role of rasagiline. 2012 , 8, 285-94	4
495	PINK1 stimulates interleukin-1 β -mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. 2012 , 69, 3301-15	26
494	Subventricular zone under the neuroinflammatory stress and Parkinson's disease. 2012 , 32, 777-85	2
493	Exposure of foetal neural progenitor cells to IL-1 β impairs their proliferation and alters their differentiation - a role for maternal inflammation?. 2012 , 120, 964-73	56
492	Central nervous system inflammation in disease related conditions: mechanistic prospects. 2012 , 1446, 144-55	61
491	Full and partial peroxisome proliferation-activated receptor- β agonists, but not β agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. 2012 , 246, 69-77	39
490	TNF- β protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. 2012 , 9, 23	197
489	Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. 2012 , 7, 42-59	220
488	Kynurenines in Parkinson's disease: therapeutic perspectives. 2012 , 119, 275-83	32
487	Genetic determinants of neuronal vulnerability to apoptosis. 2013 , 70, 71-88	10
486	A peroxisome proliferator-activated receptor- β agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. 2013 , 240, 191-203	35
485	Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2013 , 553, 63-7	3-3 45
484	Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. 2013 ,	3
483	Parkinson's Disease. 2013 , 1034-1043	
482	The presence of RANKL-OPG complex in human osteosarcoma U2OS. 2013 , 34, 356-64	1

481	Neuroimmunological processes in Parkinson's disease and their relation to α -synuclein: microglia as the referee between neuronal processes and peripheral immunity. 2013 , 5, 113-39		166
480	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. 2013 , 241, 148-55		32
479	Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. <i>Neuroscience Letters</i> , 2013 , 555, 106-11	3-3	25
478	Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. 2013 , 33, 183-9		166
477	Neural and immune mechanisms in the pathogenesis of Parkinson's disease. 2013 , 8, 189-201		109
476	Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. 2013 , 62, 803-19		196
475	Increase of oxidative stress by a novel PINK1 mutation, P209A. 2013 , 58, 160-9		16
474	Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. 2013 , 126, 541-9		210
473	The role of inflammation in sporadic and familial Parkinson's disease. 2013 , 70, 4259-73		124
472	Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation. 2013 , 331, 31-7		21
471	Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. 2013 , 8, 576-93		162
470	An Update on CSF Biomarkers of Parkinson's Disease. 2013 , 161-184		4
469	MHCII is required for α -synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. 2013 , 33, 9592-600		235
468	Colonic inflammation in Parkinson's disease. 2013 , 50, 42-8		343
467	Inhibition of glycogen synthase kinase-3 β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. 2013 , 63, 345-53		43
466	Modulating microglia activity with PPAR- δ agonists: a promising therapy for Parkinson's disease?. 2013 , 23, 112-23		47
465	Glial-mediated inflammation underlying parkinsonism. 2013 , 2013, 357805		18
464	Pluripotent stem cell-derived dopaminergic neurons as models of neurodegeneration. 2013 , 8, 649-661		0

463	New perspectives in nuclear neurology for the evaluation of Parkinson's disease. 2013 , 3, 301-23	1
462	PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. 2013 , 22, 38-44	44
461	Animal models of neurodegenerative diseases. 2013 , 35 Suppl 2, S82-91	34
460	LRRK-2 as a Key Molecule Bridging Inflammation to Parkinson's Disease. 2013 , 4, 205-215	
459	Tumor necrosis factor inhibitors - state of knowledge. 2014 , 10, 1175-85	109
458	Kynurenines in CNS disease: regulation by inflammatory cytokines. 2014 , 8, 12	215
457	Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?. 2014 , 10, 852-67	31
456	Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. 2014 , 11, 209	42
455	Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. 2014 , 2014, 275178	61
454	Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel. 2014 , 26, 720-32	12
453	Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. 2014 , 2014, 861231	368
452	Immunomodulatory Therapeutics. 2014 , 547-567	
451	Damage of neuroblastoma cell SH-SY5Y mediated by MPP+ inhibits proliferation of T-cell leukemia Jurkat by co-culture system. 2014 , 15, 10738-50	4
450	Biomarkers of Parkinson's disease. 2014 , 817-831	
449	Cytokine profiling in patients with VCP-associated disease. 2014 , 7, 29-32	11
448	Microglial TNF- α mediates enhancement of dopaminergic degeneration by brain angiotensin. 2014 , 62, 145-57	54
447	Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. 2014 , 25, 489-95	12
446	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. 2014 , 8, 369	50

445	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. 2014 , 1	4
444	Peripheral leukocyte apoptosis in patients with Parkinsonism: correlation with clinical characteristics and neuroimaging findings. 2014 , 2014, 635923	14
443	LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. 2014 , 11, 52	124
442	Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. 2014 , 67, 191-202	71
441	Analysis of cognition, motor performance and anxiety in young and aged tumor necrosis factor alpha receptor 1 and 2 deficient mice. 2014 , 258, 43-51	30
440	DHA effects in Parkinson disease depression. 2014 , 4, 61-66	10
439	Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. 2014 , 29, 527-31	37
438	Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease. 2014 , 1585, 23-36	30
437	Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?. 2014 , 13, 107-14	54
436	Neuroinflammation and Neurodegeneration. 2014 ,	5
435	Silymarin improved 6-OHDA-induced motor impairment in hemi-parkinsonian rats: behavioral and molecular study. 2014 , 22, 38	26
434	Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. 2014 , 14, 113	59
433	Inflammation in Parkinson's Disease. 2014 ,	3
432	Public health and components of particulate matter: the changing assessment of black carbon. 2014 , 64, 620-60	163
431	A novel synthetic HTB derivative, BECT inhibits lipopolysaccharide-mediated inflammatory response by suppressing the p38 MAPK/JNK and NF- κ B activation pathways. 2014 , 66, 471-9	19
430	Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. 2014 , 20, 249-60	103
429	Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease. 2014 , 25, 24-32	20
428	Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. 2014 , 4, 349-60	50

427	Three-Dimensional Blood-Brain Barrier Model for in vitro Studies of Neurovascular Pathology. 2015 , 5, 15222	132
426	Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?. 2015 , 370,	31
425	Risk of developing Parkinson's disease among patients with asthma: a nationwide longitudinal study. 2015 , 70, 1605-12	18
424	Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders. 2015 , 4, 369-408	16
423	Brain region-specific gene expression profiles in freshly isolated rat microglia. 2015 , 9, 84	74
422	Human pluripotent stem cell derived midbrain PITX3(eGFP/w) neurons: a versatile tool for pharmacological screening and neurodegenerative modeling. 2015 , 9, 104	12
421	Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. 2015 , 9, 306	27
420	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. 2015 , 2015, 620581	115
419	Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. 2015 , 2015, 610813	360
418	Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease. 2015 , 2015, 108179	12
417	Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. 2015 , 37, 335-47	25
416	TNFR1 absence protects against memory deficit induced by sepsis possibly through over-expression of hippocampal BDNF. 2015 , 30, 669-78	14
415	Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. 2015 , 4, 48-70	54
414	M1 and M2 immune activation in Parkinson's Disease: Foe and ally?. 2015 , 302, 59-73	121
413	Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. 2015 , 36, 1097-104	86
412	Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres. 2015 , 124, 136-43	11
411	Modifying welding process parameters can reduce the neurotoxic potential of manganese-containing welding fumes. 2015 , 328, 168-78	27
410	Role of β synuclein in inducing innate and adaptive immunity in Parkinson disease. 2015 , 5, 1-19	129

409	TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. 2015 , 302, 2-22	260
408	Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases. 2015 , 89, 1439-67	26
407	New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation. 2015 , 122, 1409-19	20
406	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. 2015 , 13, 68	148
405	Resveratrol attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease. 2015 , 97, 46-57	78
404	Activation of MyD88-dependent TLR1/2 signaling by misfolded α -synuclein, a protein linked to neurodegenerative disorders. 2015 , 8, 1-45	151
403	Parkinson disease with REM sleep behavior disorder: features, α -synuclein, and inflammation. 2015 , 84, 888-94	63
402	Neurotoxicity effects of atrazine-induced SH-SY5Y human dopaminergic neuroblastoma cells via microglial activation. 2015 , 11, 2915-24	26
401	Neuroinflammation in Lewy body dementia. 2015 , 21, 1398-406	50
400	Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. 2015 , 122, 1633-43	8
399	Neuroinflammation bei neurodegenerativen Erkrankungen. 2015 , 42, 402-410	1
398	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. 2015 , 273, 36-44	46
397	Perfluorooctane sulfonate mediates microglial activation and secretion of TNF- α through Ca^{2+} -dependent PKC-NF- κ B signaling. 2015 , 28, 52-60	18
396	Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings. 2015 , 29, 577-89	94
395	Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis. 2015 , 80, 79-86	52
394	TNF- α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. 2015 , 1852, 451-61	68
393	Inflammation is genetically implicated in Parkinson's disease. 2015 , 302, 89-102	145
392	Glial activation is associated with L-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. 2015 , 73, 377-87	52

391	The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?. 2015 , 1617, 155-73	59
390	VEGF-A promotes both pro-angiogenic and neurotrophic capacities for nerve recovery after compressive neuropathy in rats. 2015 , 51, 240-51	10
389	Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease. 231-241	
388	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. 249-264	
387	Role of Mitochondria-Associated Endoplasmic Reticulum Membrane in Inflammation-Mediated Metabolic Diseases. 2016 , 2016, 1851420	43
386	Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System. 2016 , 25, 147-55	9
385	Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. 2015 , 9, 507	16
384	Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. 2016 , 17,	98
383	Neuroinflammation in Movement Disorders. 2016 , 24, 771-782	2
382	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. 2016 , 31, 889-97	45
381	Glial biomarkers in human central nervous system disease. 2016 , 64, 1755-71	31
380	Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. 2016 , 31, 1543-1550	97
379	What a gastrointestinal biopsy can tell us about Parkinson's disease?. 2016 , 28, 966-74	20
378	Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. 2016 , 167, 1469-1480.e12	1558
377	Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. 2016 , 8, 368ra174	99
376	Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines. <i>Neuroscience Letters</i> , 2016 , 627, 7-12	3-3 8
375	6-Mercaptopurine attenuates tumor necrosis factor- α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation. 2016 , 13, 78	35
374	Levels of IL-8 and TNF- α decrease in Parkinson's disease. 2016 , 38, 98-102	22

373	Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model. 2016 , 36, 9375-90	65
372	Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. 2016 , 73, 1316-1324	215
371	Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α -Synuclein. 2016 , 113, 9587-92	139
370	Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects. 2016 , 123, 1255-1278	48
369	Molecular changes in the postmortem parkinsonian brain. 2016 , 139 Suppl 1, 27-58	59
368	Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. 2016 , 64, 386-95	42
367	Rho kinase II interference by small hairpin RNA ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. 2016 , 14, 4947-4956	6
366	Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. 2016 , 151, 713-720	39
365	Neuroprotective Effects of Germinated Brown Rice in Rotenone-Induced Parkinson's-Like Disease Rats. 2016 , 18, 334-46	14
364	Mediators of neuroinflammation. 2016 , 39-56	
363	Widespread brain transcriptome alterations underlie the neuroprotective actions of dietary saffron. 2016 , 139, 858-871	11
362	Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. 2016 , 137, 795-805	9
361	Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil. 2016 , 258, 36-45	12
360	Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease. 2016 , 25, 967-982	23
359	Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease. 2016 , 1382, 367-82	15
358	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. 2016 , 64, 148-66	79
357	The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease. 2016 , 319, 116-22	7
356	microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. 2016 , 36, 2383-90	147

355	Intranasal brain delivery of cationic nanoemulsion-encapsulated TNF β iRNA in prevention of experimental neuroinflammation. 2016 , 12, 987-1002	60
354	Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease. 2016 , 88, 1-15	30
353	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. 2016 , 26, 87-95	36
352	Gene Therapy for Neurological Disorders. 2016 ,	2
351	CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration. 2016 , 29, 364-80	10
350	Inflammation and B-cell Lymphoma-2 Associated X Protein Regulate Zinc-Induced Apoptotic Degeneration of Rat Nigrostriatal Dopaminergic Neurons. 2016 , 53, 5782-95	16
349	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. 2017 , 155, 171-193	89
348	Microglial phenotypes in Parkinson's disease and animal models of the disease. 2017 , 155, 57-75	143
347	Ferroptosis and cell death mechanisms in Parkinson's disease. 2017 , 104, 34-48	165
346	Parkinson's Disease. 2017 , 477-492	
345	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. 2017 , 24, 427-e6	30
344	The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease. 2017 , 66, 31-44	81
343	Downregulation of miR-7116-5p in microglia by MPP sensitizes TNF- β production to induce dopaminergic neuron damage. 2017 , 65, 1251-1263	39
342	Tau/Synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. 2017 , 32, 1066-1073	31
341	Neurosteroid allopregnanolone attenuates motor disability and prevents the changes of neurexin 1 and postsynaptic density protein 95 expression in the striatum of 6-OHDA-induced rats' model of Parkinson's disease. 2017 , 88, 1188-1197	11
340	Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32 transgenic mice. 2017 , 102, 79-88	6
339	Systemic Inflammation in Lewy Body Diseases: A Systematic Review. 2017 , 31, 346-356	18
338	Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease. 2017 , 381, 308-314	54

337	Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients. 2017 , 106, 269-278	31
336	Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease. 2017 , 51, 633-645	4
335	Depression and Anxiety in Parkinson's Disease. 2017 , 133, 623-655	59
334	Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson's Disease. 2017 , 4, 361-368	33
333	Pathological β -synuclein exacerbates the progression of Parkinson's disease through microglial activation. 2017 , 265, 30-37	85
332	l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?. 2017 , 45, 73-91	37
331	Investigations on 16-Arylideno Steroids as a New Class of Neuroprotective Agents for the Treatment of Alzheimer's and Parkinson's Diseases. 2017 , 8, 186-200	18
330	Anti-Inflammatory and Neuroprotective Effects of PGE EP4 Signaling in Models of Parkinson's Disease. 2017 , 12, 292-304	13
329	MPP-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. 2017 , 54, 6356-6377	23
328	Pyrethroid Insecticides Directly Activate Microglia Through Interaction With Voltage-Gated Sodium Channels. 2017 , 155, 112-123	31
327	Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death. 2017 , 140, 589-604	24
326	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. 2017 , 133, 303-319	124
325	Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?. 2017 , 7, 577-587	15
324	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. 2017 , 2,	47
323	Qigong Exercise May Reduce Serum TNF- α Levels and Improve Sleep in People with Parkinson's Disease: A Pilot Study. 2017 , 4,	18
322	Mitochondria in the pathophysiology of Alzheimer's and Parkinson's diseases. 2017 , 22, 854-872	69
321	Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration. 2017 , 9, 128	30
320	Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. 2017 , 9, 129	108

319	Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism. 2017 , 9, 229	7
318	Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1 β -Mediated Inflammatory Signaling through Phosphorylation of RCAN1. 2017 , 11, 125	9
317	Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders. 2017 , 11, 451	84
316	Animal Models for the Study of Human Neurodegenerative Diseases. 2017 , 1109-1129	3
315	The renin-angiotensin system: a possible new target for depression. 2017 , 15, 144	65
314	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. 2017 , 14, 164	34
313	NADPH oxidases in Parkinson's disease: a systematic review. 2017 , 12, 84	71
312	Parkinson's disease is associated with DNA methylation levels in human blood and saliva. 2017 , 9, 76	67
311	Cerebellar neurochemical and histopathological changes in rat model of Parkinson's disease induced by intrastriatal injection of rotenone. 2017 , 36, 99-108	7
310	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. 2018 , 69, 591-602	40
309	Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease. 2018 , 75, 917-920	2
308	Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. 2018 , 75, 939-946	157
307	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. 2018 , 135, 62-74	46
306	Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease. 2018 , 55, 9139-9155	31
305	LRRK2 Phosphorylation: Behind the Scenes. 2018 , 24, 486-500	13
304	Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease. 2018 , 302, 145-154	18
303	MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3. 2018 , 31, 106-115	62
302	The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease. 2018 , 70, 21-35	23

301	Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. 2018 , 55, 583-602	32
300	Cyclooxygenase-2 Directs Microglial Activation-Mediated Inflammation and Oxidative Stress Leading to Intrinsic Apoptosis in Zn-Induced Parkinsonism. 2018 , 55, 2162-2173	11
299	The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. 2018 , 80, 309-321	131
298	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. 2018 , 55, 5767-5786	77
297	Differential contribution of microglia and monocytes in neurodegenerative diseases. 2018 , 125, 809-826	47
296	Updates on immunity and inflammation in Parkinson disease pathology. 2018 , 96, 379-390	58
295	Studies on 16,17-Pyrazoline Substituted Heterosteroids as Anti-Alzheimer and Anti-Parkinsonian Agents Using LPS Induced Neuroinflammation Models of Mice and Rats. 2018 , 9, 272-283	21
294	An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. 2018 , 92, 41-82	51
293	Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. 2018 , 50, 83-90	26
292	Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. 2018 , 300, 179-187	104
291	Neurotherapeutic Effects of Bee Venom in a Rotenone-Induced Mouse Model of Parkinson Disease. 2018 , 50, 445-455	2
290	Andrographolide does not protect against neuroinflammation in a Parkinsonism model: Focus on tumor necrosis factor alpha. 2018 , 1073, 032036	
289	Immune system responses in Parkinson's disease: Early and dynamic. 2019 , 49, 364-383	52
288	Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNF α and IP-10. 2018 , 8, 16423	13
287	Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. 2018 , 15, 305	24
286	Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. 2018 , 25, 2198-2214	69
285	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. 2018 , 9, 1081	48
284	Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. 2018 , 12, 488	219

283	Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration. 2018 , 15, 333	11
282	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. 2018 , 8,	72
281	α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis. 2018 , 12, 626	17
280	Ageing, Cellular Senescence and Neurodegenerative Disease. 2018 , 19,	129
279	Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review). 2018 , 41, 1817-1825	102
278	An Aqueous Extract of Herbal Medicine ALWPs Enhances Cognitive Performance and Inhibits LPS-Induced Neuroinflammation via FAK/NF-κB Signaling Pathways. 2018 , 10, 269	8
277	Impact of monomeric, oligomeric and fibrillar alpha-synuclein on astrocyte reactivity and toxicity to neurons. 2018 , 475, 3153-3169	34
276	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. 2018 , 8, 13276	59
275	Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. 2018 , 15, 249	38
274	Role of Curcumin in Regulation of TNF-α-Mediated Brain Inflammatory Responses. 2018 , 12, 69-77	18
273	Electrolytes and Biochemical Changes in Cerebrospinal Fluid in Drowning: Experimental Rabbit Model. 2018 , 39, 236-241	6
272	Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. 2018 , 8, 479-493	25
271	Mitochondria at the Base of Neuronal Innate Immunity in Alzheimer's and Parkinson's Diseases. 2018 ,	1
270	LRRK2 is a negative regulator of phagosome maturation in macrophages. 2018 , 37,	93
269	Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. 2018 , 2018, 4784268	202
268	Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. 2018 , 11, 36	45
267	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. 2018 , 11, 164	19
266	A New Venue of TNF Targeting. 2018 , 19,	66

265	Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. 2018 , 10, 109	106
264	Regional microglia are transcriptionally distinct but similarly exacerbate neurodegeneration in a culture model of Parkinson's disease. 2018 , 15, 139	13
263	Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study. 2019 , 25, 111-123	73
262	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?. 2019 , 9, 467-488	5
261	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. 2019 , 16, 153	39
260	Parkinson's Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation. 2019 , 25, 363-376	66
259	Toll-like receptors and their therapeutic potential in Parkinson's disease and β -Synucleinopathies. 2019 , 81, 41-51	37
258	Systemic and Intravitreal Antagonism of the TNFR1 Signaling Pathway Delays Axotomy-Induced Retinal Ganglion Cell Loss. 2019 , 13, 1096	10
257	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. 2019 , 10, 3945	74
256	Neuroglia in Neurodegenerative Diseases. 2019 ,	7
255	Aquaporin-4 deficiency reduces TGF- β 1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease. 2019 , 23, 2568-2582	18
254	Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease. 2019 , 414, 8-27	12
253	Neuroprotective Potential of Small Molecule Phytochemicals in Stroke Therapy. 2019 , 155-175	1
252	Advancement in the Pathophysiology of Cerebral Stroke. 2019 ,	2
251	Microglia-mediated neuroinflammation in neurodegenerative diseases. 2019 , 94, 112-120	211
250	Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. 2019 , 9, 7202	7
249	16,17-N'-(alkyl/arylsulfonyl)pyrazoline substituted neuroprotective heterosteroids: Synthesis, molecular docking and preclinical efficacy/toxicity studies in rodents. 2019 , 148, 114-124	5
248	Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with β -Synuclein fibrils. 2019 , 129, 67-78	30

247	Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF- κ B signaling pathway in a mouse model of Parkinson's disease. 2019 , 223, 158-165	35
246	Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease. 2019 , 16, 50	15
245	The role and therapeutic potential of connexins, pannexins and their channels in Parkinson's disease. 2019 , 58, 111-118	13
244	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. 2019 , 127, 563-569	11
243	The effects of acupuncture and electroacupuncture on Parkinson's disease: Current status and future perspectives for molecular mechanisms. 2019 , 120, 12156-12166	8
242	Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?. 2019 , 10, 232	30
241	Biomarkers of Parkinson's Disease. 2019 , 895-909	
240	Anti-neuroinflammation ameliorates systemic inflammation-induced mitochondrial DNA impairment in the nucleus of the solitary tract and cardiovascular reflex dysfunction. 2019 , 16, 224	10
239	Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. 2019 , 16, 250	36
238	Pharmacological Targeting of Microglial Activation: New Therapeutic Approach. 2019 , 13, 514	56
237	Immunology of West Nile Virus Infection and the Role of Alpha-Synuclein as a Viral Restriction Factor. 2019 , 32, 38-47	17
236	Brain-Resident T Cells Following Viral Infection. 2019 , 32, 48-54	14
235	α Synuclein and Glia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?. 2019 , 39, 161-168	29
234	Knockdown of cathepsin D protects dopaminergic neurons against neuroinflammation-mediated neurotoxicity through inhibition of NF- κ B signalling pathway in Parkinson's disease model. 2019 , 46, 337-349	9
233	The risk of Parkinson's disease in inflammatory bowel disease: A systematic review and meta-analysis. 2019 , 51, 38-42	53
232	Gene Dysfunction Mediates Immune Response to Dopaminergic Degeneration in Parkinson's Disease. 2019 , 10, 803-811	2
231	The unlikely partnership between LRRK2 and α Synuclein in Parkinson's disease. 2019 , 49, 339-363	22
230	The role of catecholamines in HIV neuropathogenesis. 2019 , 1702, 54-73	23

229	Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort. 2020 , 267, 513-521		3
228	Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. <i>Neuroscience Letters</i> , 2020 , 714, 134576	3-3	16
227	Systemic activation of NLRP3 inflammasome and plasma β synuclein levels are correlated with motor severity and progression in Parkinson's disease. 2020 , 17, 11		49
226	Innate and adaptive immune responses in Parkinson's disease. 2020 , 252, 169-216		29
225	Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease. 2020 , 325, 113159		36
224	Risk of Parkinson's disease among patients with herpes zoster: a nationwide longitudinal study. 2020 , 25, 797-802		3
223	NF- κ B-Mediated Neuroinflammation in Parkinson's Disease and Potential Therapeutic Effect of Polyphenols. 2020 , 37, 491-507		48
222	Asparagine endopeptidase inhibitor protects against fenpropathrin-induced neurodegeneration via suppressing β synuclein aggregation and neuroinflammation. 2020 , 888, 173586		1
221	Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells. 2020 , 144, 151-164		53
220	Tumour necrosis factor induces increased production of extracellular amyloid- β and β synuclein-containing aggregates by human Alzheimer's disease neurons. 2020 , 2, fcaa146		5
219	Activation of TNFR1 and TLR4 following oxygen glucose deprivation promotes mitochondrial fission in C6 astroglial cells. 2020 , 75, 109714		2
218	The Role of Glial Mitochondria in β synuclein Toxicity. 2020 , 8, 548283		7
217	Microorganisms that are related with increased risk for Parkinson's disease. 2020 ,		1
216	Immunoinflammatory Aspects of Parkinson's Disease. 2020 , 50, 1127-1135		
215	Neuroinflammation and protein pathology in Parkinson's disease dementia. 2020 , 8, 211		30
214	Overview of General and Discriminating Markers of Differential Microglia Phenotypes. 2020 , 14, 198		106
213	Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series. 2020 , 144, 105027		16
212	Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease. 2020 , 90, 26-46		28

211	Plasma immune markers in an idiopathic REM sleep behavior disorder cohort. 2020 , 78, 145-150	5
210	Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinson's disease rat model. 2020 , 90, 16-25	10
209	Computational modelling of TNF-related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration. 2020 , 5,	2
208	Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways. 2020 , 21,	11
207	In Search of Effective Treatments Targeting β Synuclein Toxicity in Synucleinopathies: Pros and Cons. 2020 , 8, 559791	9
206	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. 2020 , 9,	21
205	P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. 2020 , 21,	23
204	MMP13 Expression Is Increased Following Mutant β Synuclein Exposure and Promotes Inflammatory Responses in Microglia. 2020 , 14, 585544	2
203	Biological effects of inhaled hydraulic fracturing sand dust VII. Neuroinflammation and altered synaptic protein expression. 2020 , 409, 115300	6
202	Multiple-Hit Hypothesis in Parkinson's Disease: LRRK2 and Inflammation. 2020 , 14, 376	20
201	Inflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery. 2020 , 33, 191-210	27
200	A systematic review of minor phytocannabinoids with promising neuroprotective potential. 2020 , 177, 4330-4352	17
199	Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. 2020 , 21,	40
198	The pesticide fipronil injected into the substantia nigra of male rats decreases striatal dopamine content: A neurochemical, immunohistochemical and behavioral study. 2020 , 384, 112562	10
197	The Immunomodulatory Effects of Systematic Exercise in Older Adults and People with Parkinson's Disease. 2020 , 9,	8
196	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. 2020 , 25,	14
195	Cell-free microRNAs in Parkinson's disease: potential biomarkers that provide new insights into disease pathogenesis. 2020 , 58, 101023	11
194	Parkinson disease and the immune system - associations, mechanisms and therapeutics. 2020 , 16, 303-318	105

193	Mitochondrial DNA in inflammation and immunity. 2020 , 21, e49799	159
192	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. 2020 , 9,	23
191	Anti-Inflammatory and Anti-Migratory Activities of Isoquinoline-1-Carboxamide Derivatives in LPS-Treated BV2 Microglial Cells via Inhibition of MAPKs/NF- κ B Pathway. 2020 , 21,	12
190	Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. 2021 , 16, 390-402	16
189	Peripheral inflammation exacerbates α Synuclein toxicity and neuropathology in Parkinson's models. 2021 , 47, 43-60	16
188	Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. 2021 , 196, 101890	49
187	Inflammation in Experimental Models of α Synucleinopathies. 2021 , 36, 37-49	14
186	Cypermethrin Induces the Activation of Rat Primary Microglia and Expression of Inflammatory Proteins. 2021 , 71, 1275-1283	0
185	Battery-free, wireless, and flexible electrochemical patch for in situ analysis of sweat cortisol via near field communication. 2021 , 172, 112782	35
184	Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. 2021 , 162, 160-178	5
183	Immunomodulation with IL-17 and TNF- α in spondyloarthritis: focus on the eye and the central nervous system. 2021 , 13, 1759720X211025894	1
182	Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism. 2021 , 377, 1-10	2
181	Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities. 2021 , 35, 11-19	2
180	Parkinson's disease. 2021 , 1-171	1
179	Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches. 2021 , 79, 931-948	10
178	Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. 2020 , 14, 580311	7
177	Central inhibition of P2Y ₁₂ R differentially regulates survival and neuronal loss in MPTP-induced Parkinsonism in mice.	
176	Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives. 2021 , 12, 611761	7

175	Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. 2021 , 16, 281-294	4
174	Cytokine Profile in Plasma Extracellular Vesicles of Parkinson's Disease and the Association with Cognitive Function. 2021 , 10,	6
173	Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities. 2021 , 10,	7
172	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. 2021 , 10,	11
171	Interferon- γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia. 2021 , 39, 705-719	1
170	-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. 2021 , 4, 980-1000	4
169	CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease. 2021 , 144, 2047-2059	21
168	Inflammatory Responses to Monomeric and Aggregated β Synuclein in Peripheral Blood of Parkinson Disease Patients. 2021 , 15, 639646	7
167	Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?. 2021 , 7, 26	9
166	G-CSF reduces loss of dopaminergic neurons by inhibiting TNF- α and IL-1 β in mouse model of Parkinson's disease. 2021 , 1-12	
165	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. 2021 , 12, 644294	3
164	T Cells Limit Accumulation of Aggregate Pathology Following Intrastratial Injection of β Synuclein Fibrils. 2021 , 11, 585-603	3
163	TNF α increases Tyrosine Hydroxylase expression in human monocytes.	
162	Epigenetic Regulation of Neuroinflammation in Parkinson's Disease. 2021 , 22,	12
161	Oxidative stress and regulated cell death in Parkinson's disease. 2021 , 67, 101263	28
160	Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. 2021 , 7, 41	7
159	The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice. 2021 , 85, 254-264	3
158	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. 2021 , 8, 655123	2

157	TNF α increases tyrosine hydroxylase expression in human monocytes. 2021 , 7, 62	1
156	Noscapine Prevents Rotenone-Induced Neurotoxicity: Involvement of Oxidative Stress, Neuroinflammation and Autophagy Pathways. 2021 , 26,	2
155	DRD4 (Dopamine D4 Receptor) Mitigate Abdominal Aortic Aneurysm via Decreasing P38 MAPK (mitogen-activated protein kinase)/NOX4 (NADPH Oxidase 4) Axis-Associated Oxidative Stress. 2021 , 78, 294-307	1
154	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and α Synucleinopathy. 2021 , 11,	0
153	Neurodegenerative disorders and the current state, pathophysiology and management of Parkinson's disease. 2021 ,	
152	Mitochondrial dysfunction in adult midbrain dopamine neurons triggers an early immune response. 2021 , 17, e1009822	0
151	Role of Inflammation in Lewy Body Dementia. 2021 , 190-212	
150	Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. 2021 , 22,	18
149	Inflammation in parkinson's disease. 2007 , 249-279	21
148	Inflammatory Changes and Apoptosis in Parkinson's Disease. 2002 , 259-263	2
147	TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. 2011 , 691, 539-40	54
146	Prospects for New Treatment Options in Neurodegenerative Diseases. 2012 , 165-171	1
145	Neuroinflammation and Parkinson's Disease. 2014 , 885-912	1
144	Cytokines in Parkinson's Disease. 1998 , 407-412	2
143	Prenatal Lipopolysaccharide Alters Postnatal Dopamine in the Laboratory Rat. 2002 , 209-212	3
142	Inflammatory Mediators in Alzheimer's Disease. 1997 , 177-198	8
141	Tumor Necrosis Factor. 1998 , 163-183	4
140	Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. 2019 , 1201, 275-353	4

139	Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. 2007 , 113-20	115
138	Parkinson's Disease and Aging. 2016 , 229-255	1
137	Selegiline as immunostimulant--a novel mechanism of action?. 1998 , 52, 321-8	20
136	Apoptosis in neurodegenerative disorders. 1997 , 50, 125-40	41
135	Parkinson's Disease; Neurodegeneration as Systemic Disease. 2015 , 69-87	1
134	Microglia in Parkinson's Disease. 2019 , 1175, 335-353	56
133	Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. 1997 , 28, 1233-44	591
132	Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. 2011 , 6, e16038	127
131	Fractalkine Signaling Regulates the Inflammatory Response in an α -Synuclein Model of Parkinson Disease. 2015 , 10, e0140566	46
130	ASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease. 2016 , 11, e0165235	12
129	Abrogation of the Circadian Nuclear Receptor REV-ERB β Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration. 2018 , 41, 742-752	9
128	Resveratrol Normalizes Hyperammonemia Induced Pro-Inflammatory and Pro-Apoptotic Conditions in Rat Brain. 2016 , 4,	3
127	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease. 2019 , 26, 3719-3753	23
126	The Role of LRRK2 in Neurodegeneration of Parkinson Disease. 2018 , 16, 1348-1357	39
125	Targeting TNF- α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. 2011 , 10, 391-403	150
124	Cellular Senescence in Neurodegenerative Diseases. 2020 , 14, 16	78
123	TNF-Mediated Homeostatic Synaptic Plasticity: From to Models. 2020 , 14, 565841	16
122	Chemically Induced Models of Parkinson's Disease: History and Perspectives for the Involvement of Ferroptosis. 2020 , 14, 581191	6

121	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. 2020 , 14, 443	21
120	The α -formyl peptide receptors: contemporary roles in neuronal function and dysfunction. 2020 , 15, 1191-1198	8
119	Elevated levels of Interleukin (IL)-1 β , IL-6, tumor necrosis factor- α , epidermal growth factor, and α 2-microglobulin levels in gingival crevicular fluid during human Orthodontic tooth movement (OTM). 2019 , 8, 1602-1606	8
118	Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. 2017 , 8, 65	37
117	The role of neuroinflammation on the pathogenesis of Parkinson's disease. 2010 , 43, 225-32	112
116	Reactive Oxygen Species in Neurodegenerative Diseases: Implications in Pathogenesis and Treatment Strategies.	2
115	Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery. 2021 , 11,	8
114	Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. 2021 , 12, 5907	14
113	Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders. 2021 , 2021, 5005136	9
112	Contribution of Intracellular Non-Haem Iron, NF- κ B Activation and Inflammatory Responses to Neurodegeneration in Parkinson's Disease: Prospects for Neuroprotection. 2000 , 277-288	
111	Cytokines and Neurotrophins in Parkinson's Disease: Involvement in Apoptosis. 2002 , 265-270	
110	Cytokines and Neurodegeneration. 2005 , 163-191	
109	The In Vitro and In Vivo Molecular Mechanisms of Neuroprotection by the Major Green Tea Polyphenol, (R)-Epigallocatechin-3-gallate, with Special Reference to Parkinson's Disease. 2005 , 155-174	
108	Contribution of Receptors, Transcription Factors, and Genes in the Induction of Neuroinflammation. 2014 , 111-142	
107	Proinflammatory Chemical Signaling: Cytokines. 2014 , 145-173	1
106	Clinical Aspects of Inflammation in Parkinson's Disease. 2014 , 189-204	2
105	References. 1995 , 707-850	
104	Role of Adenosine A2A Receptors in the Control of Neuroinflammation: Relevance for Parkinson's Disease. 2015 , 81-99	

103 Ibuprofen in Prevention of Neurodegenerative Diseases. 547-570

102 Changes in the Immune System in Parkinson's Disease. **2018**, 1-21

101 Changes in the Immune System in Parkinson's Disease. **2019**, 2353-2373

100 Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson's Disease. **2020**, 1-21

99 Phf15 is a novel transcriptional repressor regulating inflammation in mouse microglia.

98 Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. **2020**, 1-40

97 Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson's Disease. **2020**, 1-21 1

96 Ageing and MPTP-sensitivity depend on molecular and ultrastructural signatures of astroglia and microglia in mice substantia nigra. 1

95 Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum.. **2022**, 148, 41-50 0

94 Neurons and Plasticity: What Do Glial Cells Have to Do with This?. **2020**, 13-46

93 Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. **2020**, 335-370

92 Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson's disease.

91 [Immunological aspects of Parkinson's disease]. **2020**, 120, 110-119 2

90 T cells limit accumulation of aggregate pathology following intrastriatal injection of α -synuclein fibrils. 1

89 Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. **2022**, 202, 108870 3

88 NF- κ B in Aging and Disease. **2011**, 2, 449-65 140

87 Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/ β -catenin dependent pathways in a mice model of Parkinson's disease. **2015**, 8, 2354-64 24

86 Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms. **2021**, 163, 105580 4

85	Efficacy of Human Umbilical Cord Blood-Mononuclear Cell Transplantation for MSA Treatment and Its Effects on Changes in T-Cell Subsets in Peripheral Blood and Inflammatory Factors.. 2021 , 2021, 5290766	0
84	Immune response during idiopathic Parkinson's disease: From humans to animal models. 2021 , 2, 261-301	0
83	Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF- α and IL-1 β evidence from early experimental model of Parkinson's disease.. 2022 , 1-10	0
82	Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells.. 2022 , 354, 109808	0
81	A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases.. 2021 , 15, 787258	8
80	Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases.. 2022 , 17, 1675-1684	4
79	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.. 2022 , 19, 19	5
78	Neurodegeneration by β synuclein-specific T cells in AAV-A53T- β synuclein Parkinson's disease mice.. 2022 , 101, 194-194	1
77	Role of exosomes in the pathogenesis of inflammation in Parkinson's disease.. 2022 , 17, 1898-1906	3
76	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. 2022 ,	1
75	Mitochondria-targeted drug delivery systems for the effective treatment of neurodegenerative disorders. 2022 , 129-150	
74	Immunotherapeutic interventions in Parkinson's disease: Focus on β synuclein.. 2022 , 129, 381-433	0
73	Leukotriene Signaling as a Target in β synucleinopathies.. 2022 , 12,	0
72	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers.. 2022 , 13, 834580	2
71	Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.. 2022 , 11,	2
70	TRACKING INNATE IMMUNE ACTIVATION IN A MOUSE MODEL OF PARKINSON'S DISEASE USING TREM1 AND TSPO PET TRACERS.. 2022 ,	0
69	Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model.. 2022 , 119,	6
68	Central Inflammatory Cytokines in Tuberculous Meningitis: A Systematic Review and Meta-analysis.. 2022 , 42, 95-107	0

67	Inflammation and immune dysfunction in Parkinson disease.. 2022 ,	23
66	Treatment; Moussa B.H. Youdim.. 2022 , 1	
65	Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease.. 2022 , 78, 101618	2
64	Biomarker of Neuroinflammation in Parkinson's Disease.. 2022 , 23,	5
63	Immune responses in the Parkinson's disease brain.. 2022 , 105700	0
62	Role of Astrocyte Dysfunction in Parkinson's Disease Pathogenesis. 2022 , 243-291	
61	Table_1.DOCX. 2020 ,	
60	Data_Sheet_1.docx. 2018 ,	
59	Image_1.pdf. 2018 ,	
58	Image_1.pdf. 2020 ,	
57	Image_1.TIFF. 2018 ,	
56	Diagnosis of Parkinson's disease by investigating the inhibitory effect of serum components on P450 inhibition assay.. 2022 , 12, 6622	0
55	Microorganisms associated with increased risk of Parkinson's disease. 2022 ,	
54	Immune-related biomarkers for Parkinson's disease. 2022 , 170, 105771	1
53	Neuroinflammation in Parkinson's Disease [Putative Pathomechanisms and Targets for Disease-Modification. 2022 , 13,	3
52	Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease. 2022 , 1-18	0
51	Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. 2022 , 105804	0
50	DAT and TH expression marks human Parkinson's disease in peripheral immune cells. 2022 , 8,	0

49	Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α -synuclein mouse model of Parkinson's disease. 2022 , 171, 105798	0
48	NF- κ B Regulation by Gut Microbiota Decides Homeostasis or Disease Outcome During Ageing. 10,	1
47	The Role of ASIC1a in Inflammatory Immune Diseases: A Potential Therapeutic Target. 13,	0
46	Efficacy of Phytochemicals and Natural Products in the Management/Treatment of Neurodegenerative Diseases. 2022 , 178-210	
45	G2019S LRRK2 Mutation Enhances MPP ⁺ -Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons. 16,	
44	Neuroinflammation in early, late and recovery stages in a progressive parkinsonism model in rats. 16,	
43	Genome integrity and inflammation in the nervous system. 2022 , 119, 103406	0
42	Neuroinflammation and Parkinson's Disease—from Neurodegeneration to Therapeutic Opportunities. 2022 , 11, 2908	5
41	Brain and systemic inflammation in de novo Parkinson's disease.	0
40	Activity of a Novel Anti-Inflammatory Agent F-3,6 β -dithiopomalidomide as a Treatment for Traumatic Brain Injury. 2022 , 10, 2449	0
39	Trimethylamine N-oxide: role in cell senescence and age-related diseases.	1
38	Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD.	0
37	Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?. 2022 , 1-18	0
36	Effect of citronellol on oxidative stress, neuroinflammation and autophagy pathways in an in vivo model of Parkinson's disease. 2022 , e11434	1
35	Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson's Disease. 2022 , 3127-3147	0
34	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. 2022 , 25-63	0
33	Microglia and astrocyte activation is region-dependent in the α -synuclein mouse model of Parkinson's disease.	0
32	A combined panel of salivary biomarkers in de novo Parkinson's Disease.	0

31	The complex role of inflammation and gliotransmitters in Parkinson's disease. 2023 , 176, 105940	0
30	Altered expression of glycobiology-related genes in Parkinson's disease brain. 15,	0
29	Pathogenesis of α -Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective. 2022 , 23, 14753	2
28	Mechanisms of Autoimmune Cell in DA Neuron Apoptosis of Parkinson's Disease: Recent Advancement. 2022 , 2022, 1-20	1
27	Association between Heavy Metal Exposure and Parkinson's Disease: A Review of the Mechanisms Related to Oxidative Stress. 2022 , 11, 2467	1
26	Dopamine, Immunity and Disease. PHARMREV-AR-2022-000618	1
25	Microglial autophagy in Alzheimer's disease and Parkinson's disease. 14,	1
24	Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. 2023 , 175517	1
23	Linagliptin counteracts rotenone's toxicity in non-diabetic rat model of Parkinson's disease: Insights into the neuroprotective roles of DJ-1, SIRT-1/Nrf-2 and implications of HIF1- α . 2023 , 941, 175498	0
22	Kinases control of regulated cell death revealing druggable targets for Parkinson's disease. 2023 , 85, 101841	1
21	Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T- α -Synuclein Parkinson's disease mice. 2022 , 19,	0
20	Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson's Disease. 2023 , 16, 152	0
19	Deep brain stimulation improves central nervous system inflammation in Parkinson's disease: Evidence and perspectives.	0
18	Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson's Disease. 2023 , 24, 2642	1
17	TREM2 deficiency aggravates NLRP3 inflammasome activation and pyroptosis in MPTP-induced PD mice and LPS-induced BV2 cells.	0
16	Systemic lupus erythematosus is associated with increased risk of Parkinson's disease. 2023 , 15, 1759720X2311526	
15	Serum inflammatory cytokines levels and the correlation analyses in Parkinson's disease. 11,	0
14	Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease. 2023 , 67-93	0

- 13 Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders. **2023**, 95-106 ○
- 12 Signaling pathways in Parkinson disease: molecular mechanisms and therapeutic interventions. **2023**, 8, ○
- 11 Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease Models. **2023**, 12, 582 ○
- 10 Brain and Systemic Inflammation in De Novo Parkinson's Disease. ○
- 9 Quantitative and causal analysis for inflammatory genes and the risk of Parkinson disease. 14, ○
- 8 Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson disease. ○
- 7 Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD. **2023**, 9, ○
- 6 Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. **2023**, 435-458 ○
- 5 Roles of neuropathology-associated reactive astrocytes: a systematic review. **2023**, 11, ○
- 4 Association between Inflammatory Bowel Disease and Subsequent Development of Restless Legs Syndrome and Parkinson Disease: A Retrospective Cohort Study of 35,988 Primary Care Patients in Germany. **2023**, 13, 897 ○
- 3 Microglia and Astrocytes Dysfunction and Key Neuroinflammation-Based Biomarkers in Parkinson Disease. **2023**, 13, 634 ○
- 2 Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson disease. **2023**, 130, 627-646 ○
- 1 Post-inflammatory administration of N -acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson's disease. ○